Real-World DATA Analysis of Antiretroviral Treatment for HIV-Infected Children in Ukraine
Author(s)
Vysotska O1, Piniazhko O2, Vysotskyi V1, Masheiko A3, Serediuk V4, Leleka M4
1The Educational and Research Center – Ukrainian Family Medicine Training Center of Bogomolets National Medical University, Kyiv, Ukraine, 2State Expert Center (SEC) of Ministry of Health, Kyiv, Ukraine, 3State Expert Center of the Ministry of Health of Ukraine, Kyiv, BC, Ukraine, 4State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine
OBJECTIVES. Analysis of the real-world data is an essential component in defining whether the medicine expenditures and prescriptions are reasonably allocated. Therefore, real-world data analysis of treatment for HIV-infected children in Ukraine was conducted. METHODS. ABC/VEN-analysis has been recommended by the WHO for analysis of the feasibility of using medical resources in real clinical practice. The subject of this analysis was the medical documentation of 72 children with HIV/AIDS from the Center for Infectious Diseases "Clinic for the treatment of children with HIV/AIDS" of National Children's Specialized Hospital “OKHMATDYT” of the MoH of Ukraine for the period 2017–2019. The direct medical costs were calculated based on drug manufacturers' prices from the MoH registry from 20.08.2020. RESULTS. It was found that for 72 pediatric patients were prescribed 13 antiretroviral schemes. The average cost of the annual course was USD 854.19 per one patient and USD 61,782.35 for all prescriptions. ABC-analysis showed that category A consisted of 4 schemes, B - 3 schemes and category C - 6 schemes. In the cost structure schemes tenofovir disoproxil fumarate/emtricitabine combined with etravirine (TDF/FTC+ETR), lamivudine/zidovudine combined with lopinavir/ritonavir (AZT/3TC+LPV/r), tenofovir disoproxil fumarate/emtricitabine combined with lopinavir/ritonavir (TDF/FTC+LPV/r) and abacavir/lamivudine combined with lopinavir/ritonavir (ABC/ЗTС+LPV/r) had the highest shares (29.6%, 27.5%, 13.3% and 8.7% respectively). The scheme with TDF/FTC+ETR were prescribed only to 5.5% (4/72) patients. Significant expenses for this scheme were caused by the high cost of etravirine. Etravirine is neither included in the clinical guideline of antiretroviral treatment nor the 7st WHO Model List of Essential Medicines for Children nor the National List of Essential Medicines. Etravirine is considered as a non-essential drug. CONCLUSIONS. ABC/VEN analysis of the real-world data showed that medicines for the treatment for HIV-infected pediatric patients in Ukraine mainly correspond to the international treatment guidelines and regulatory lists which provides reliable additional evidence for the health technology assessment.
Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada
Value in Health, Volume 24, Issue 5, S1 (May 2021)
Code
PIN78
Topic
Economic Evaluation, Health Policy & Regulatory, Health Service Delivery & Process of Care, Real World Data & Information Systems
Topic Subcategory
Distributed Data & Research Networks, Hospital and Clinical Practices, Public Spending & National Health Expenditures
Disease
Infectious Disease (non-vaccine)
Explore Related HEOR by Topic